Glycocholic acid sodium

Name: Glycocholic acid sodium
Brand: MedChemExpress
SKU: HY-N1423A
Rating: 4.5 (1 reviews)

Cat. No.: HY-N1423A Purity: ≥97.0%: FAQs
Data Sheet SDS COA Handling Instructions

Molarity Calculator

Glycocholic acid sodium is an orally active bile acid with anticancer activity, targeting against pump resistance-related and non-pump resistance-related pathways.

For research use only. We do not sell to patients.

Glycocholic acid sodium Chemical Structure

CAS No. : 863-57-0

Size	Price	Stock	Quantity

Free Sample (0.1 - 0.5 mg)		Apply Now
Solid + Solvent (Highly Recommended)
10 mM * 1 mL in DMSO ready for reconstitution	USD 55	In-stock	Estimated Time of Arrival: December 31
Solution
10 mM * 1 mL in DMSO	USD 55	In-stock	Estimated Time of Arrival: December 31
Solid
50 mg	USD 50	In-stock	Estimated Time of Arrival: December 31
100 mg	USD 60	In-stock	Estimated Time of Arrival: December 31
500 mg	USD 80	In-stock	Estimated Time of Arrival: December 31
1 g		Get quote
5 g		Get quote

or Bulk Inquiry

* Please select Quantity before adding items.

This product is a controlled substance and not for sale in your territory.

Customer Review

Based on 1 publication(s) in Google Scholar

Other Forms of Glycocholic acid sodium:

Glycocholic acid In-stock
Glycocholic acid hydrate Get quote
Sodium glycocholate hydrate, 98% Get quote

1 Publications Citing Use of MCE Glycocholic acid sodium

•Nat Commun. 2024 Sep 19;15(1):8221. [Abstract]

Featured Recommendations

•Related Screening Libraries:

•Related Small Molecules:

•Related Proteins:

Biological Activity
Purity & Documentation
References
Customer Review

Description

Glycocholic acid sodium is an orally active bile acid with anticancer activity, targeting against pump resistance-related and non-pump resistance-related pathways^[1].

IC₅₀ & Target

Microbial Metabolite

Human Endogenous Metabolite

In Vitro

Glycocholic acid (GC) increases the cytotoxicity of epirubicin, significantly increases the intracellular accumulation of epirubicin in Caco-2 cells and the absorption of epirubicin in rat small intestine, and intensified epirubicin-induced apoptosis. Glycocholic acid and epirubicin significantly reduce mRNA expression levels of human intestinal MDR1, MDR-associated protein (MRP)1, and MRP2; downregulate the MDR1 promoter region; suppress the mRNA expression of Bcl-2; induce the mRNA expression of Bax; and significantly increase the Bax-to-Bcl-2 ratio and the mRNA levels of p53, caspase-9 and -3. A combination of anticancer drugs with Glycocholic acid can control MDR via a mechanism that involves modulating P-gp and MRPs as well as regulating apoptosis-related pathways^[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Clinical Trial

Molecular Weight

487.60

Formula

C₂₆H₄₂NNaO₆

CAS No.

863-57-0

Appearance

Solid

Color

White to off-white

SMILES

O[C@H]1[C@@]2([H])[C@@]3([H])[C@@]([C@@](CC3)([H])[C@H](C)CCC(NCC(O[Na])=O)=O)([C@H](C[C@]2([H])[C@@]4([C@](C[C@@H](CC4)O)([H])C1)C)O)C

Shipping

Room temperature in continental US; may vary elsewhere.

Storage

4°C, sealed storage, away from moisture

*In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture)

Solvent & Solubility

In Vitro:

DMSO : ≥ 100 mg/mL (205.09 mM; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)

*"≥" means soluble, but saturation unknown.

Preparing
Stock Solutions

Concentration Solvent Mass	1 mg	5 mg	10 mg

1 mM	2.0509 mL	10.2543 mL	20.5086 mL
5 mM	0.4102 mL	2.0509 mL	4.1017 mL
10 mM	0.2051 mL	1.0254 mL	2.0509 mL

View the Complete Stock Solution Preparation Table

* Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.

Molarity Calculator
Dilution Calculator

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Concentration _(start) × Volume _(start) = Concentration _(final) × Volume _(final)

This equation is commonly abbreviated as: C₁V₁ = C₂V₂

Concentration _(start)

Volume _(start)

Concentration _(final)

Volume _(final)

In Vivo:

Select the appropriate dissolution method based on your experimental animal and administration route.

For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for in vivo experiments, it is recommended to prepare freshly and use it on the same day.
The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.

Protocol 1

Add each solvent one by one: 10% DMSO 40% PEG300 5% Tween-80 45% Saline
Solubility: ≥ 2.5 mg/mL (5.13 mM); Clear solution

This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown).
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.
Preparation of Saline: Dissolve 0.9 g sodium chloride in ddH₂O and dilute to 100 mL to obtain a clear Saline solution.
Protocol 2

Add each solvent one by one: 10% DMSO 90% (20% SBE-β-CD in Saline)
Solubility: ≥ 2.5 mg/mL (5.13 mM); Clear solution

This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown).
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 900 μL 20% SBE-β-CD in Saline, and mix evenly.
Preparation of 20% SBE-β-CD in Saline (4°C, storage for one week): 2 g SBE-β-CD powder is dissolved in 10 mL Saline, completely dissolve until clear.
Protocol 3

Add each solvent one by one: 10% DMSO 90% Corn Oil
Solubility: ≥ 2.5 mg/mL (5.13 mM); Clear solution

This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown). If the continuous dosing period exceeds half a month, please choose this protocol carefully.
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 900 μL Corn oil, and mix evenly.

In Vivo Dissolution Calculator

Please enter the basic information of animal experiments:

Dosage

mg/kg

Animal weight
(per animal)

Dosing volume
(per animal)

μL

Number of animals

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.

Please enter your animal formula composition:

DMSO +

Tween-80 +

Saline

Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.

The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).

Calculation results:

Working solution concentration: mg/mL

Method for preparing stock solution: mg drug dissolved in μL DMSO (Stock solution concentration: mg/mL).

*In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture)

The concentration of the stock solution you require exceeds the measured solubility. The following solution is for reference only. If necessary, please contact MedChemExpress (MCE).

Method for preparing in vivo working solution for animal experiments: Take μL DMSO stock solution, add μL . μL , mix evenly, next add μL Tween 80, mix evenly, then add μL Saline.

If the continuous dosing period exceeds half a month, please choose this protocol carefully.

Please ensure that the stock solution in the first step is dissolved to a clear state, and add co-solvents in sequence. You can use ultrasonic heating (ultrasonic cleaner, recommended frequency 20-40 kHz), vortexing, etc. to assist dissolution.

Purity & Documentation

Purity: ≥97.0%

Select Batch:

Data Sheet (273 KB) SDS (393 KB)

COA (249 KB) HNMR (129 KB)

Handling Instructions (2659 KB)

References

[1]. Lo YL, et al. Inhibit multidrug resistance and induce apoptosis by using glycocholic acid and epirubicin. Eur J Pharm Sci. 2008 Sep 2;35(1-2):52-67. [Content Brief]

Complete Stock Solution Preparation Table

Optional Solvent	Concentration Solvent Mass	1 mg	5 mg	10 mg	25 mg

DMSO	1 mM	2.0509 mL	10.2543 mL	20.5086 mL	51.2715 mL
	5 mM	0.4102 mL	2.0509 mL	4.1017 mL	10.2543 mL
	10 mM	0.2051 mL	1.0254 mL	2.0509 mL	5.1272 mL
	15 mM	0.1367 mL	0.6836 mL	1.3672 mL	3.4181 mL
	20 mM	0.1025 mL	0.5127 mL	1.0254 mL	2.5636 mL
	25 mM	0.0820 mL	0.4102 mL	0.8203 mL	2.0509 mL
	30 mM	0.0684 mL	0.3418 mL	0.6836 mL	1.7091 mL
	40 mM	0.0513 mL	0.2564 mL	0.5127 mL	1.2818 mL
	50 mM	0.0410 mL	0.2051 mL	0.4102 mL	1.0254 mL
	60 mM	0.0342 mL	0.1709 mL	0.3418 mL	0.8545 mL
	80 mM	0.0256 mL	0.1282 mL	0.2564 mL	0.6409 mL
	100 mM	0.0205 mL	0.1025 mL	0.2051 mL	0.5127 mL